Chewy Is Down 25% This Year. Investors Should Be Eager to Buy.

Chewy said it will acquire Modern Animal, expanding its veterinary footprint to 47 clinics from 18 and reinforcing its push into higher-margin health services. The company also disclosed that autoship accounted for 84% of fiscal 2025 net sales, underscoring the durability of its recurring revenue model. Shares are down 25% year to date and 35% over the past 12 months, which the article frames as a potential entry point rather than a deterioration in fundamentals.

Analysis

The market is treating CHWY like a single-factor consumer discretionary name, but the setup is increasingly that of a vertically integrated recurring-revenue platform. The key second-order effect is not just better mix; it is higher customer lifetime value and lower churn as veterinary, pharmacy, and private-label attach deepen the basket. That matters because the market will eventually re-rate the company on transaction quality, not just top-line growth, if management can show sustained margin expansion over the next 2-4 quarters.

The acquisition angle is also strategically important for competitive dynamics. By pushing into care delivery, CHWY creates a proprietary funnel that is harder for generalist pet retailers and marketplaces to replicate, while simultaneously reducing dependence on price competition in core consumables. The likely loser is the broader pet retail cohort, because if CHWY successfully monetizes health services, it can subsidize acquisition costs and intensify share gains in autoship without needing to win purely on discounting.

The contrarian issue is that the stock may be at the point where sentiment has overshot the fundamentals. If autoship remains sticky through a softer consumer backdrop, the downside from macro weakness should compress while the upside from mix shift becomes more visible; that is a classic multiple-expansion inflection. The main risk is execution: integrating a clinic network can temporarily drag margins and absorb capital, so the next two quarters are about proof of operating leverage, not just strategic narrative.

For the broader tape, this is mildly positive for other consumer platforms with subscription mechanics and healthcare attach, but it is not a broad retail beta trade. The signal is that investors are willing to pay for recurring revenue plus services even in a challenged discretionary environment, which could support premium valuations for vertically integrated models while punishing pure-play commodity sellers.

Key Decisions for Investors

• Long CHWY into the next 1-2 earnings prints; use a staggered entry near current levels with a 6-12 month horizon. Risk/reward is favorable if management shows even modest margin inflection, as the stock can rerate quickly from depressed multiples.
• Buy CHWY call spreads 3-6 months out rather than outright stock for defined risk. A moderate upside move is plausible if the market starts capitalizing the clinic/pharmacy mix shift, but the position should be structured to survive integration noise.
• Pair trade: long CHWY / short a weaker pet retail or consumer-discretionary laggard with lower recurring revenue quality. The thesis is that the market will increasingly reward subscription-plus-services models over pure product resellers in a soft demand environment.
• If CHWY rallies sharply before visible post-deal execution, trim 25-30% and hold the rest for the integration window. The catalyst sequence matters more than the headline acquisition; near-term moves may overshoot the fundamental path.
• Avoid shorting CHWY into weakness unless autoship retention deteriorates; the recurring mix gives the stock a floor that makes downside asymmetric only if the core customer relationship breaks.